OA12362A - Substituted imidazoles as tafia inhibitors. - Google Patents

Substituted imidazoles as tafia inhibitors. Download PDF

Info

Publication number
OA12362A
OA12362A OA1200300039A OA1200300039A OA12362A OA 12362 A OA12362 A OA 12362A OA 1200300039 A OA1200300039 A OA 1200300039A OA 1200300039 A OA1200300039 A OA 1200300039A OA 12362 A OA12362 A OA 12362A
Authority
OA
OAPI
Prior art keywords
formula
compound
preparation
hydrogen
compounds
Prior art date
Application number
OA1200300039A
Other languages
English (en)
French (fr)
Inventor
Charlotte Moira Norfo Allerton
Julian Blagg
Mark Edward Bunnage
John Steele
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0020346A external-priority patent/GB0020346D0/en
Priority claimed from GB0027409A external-priority patent/GB0027409D0/en
Priority claimed from GB0029556A external-priority patent/GB0029556D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of OA12362A publication Critical patent/OA12362A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
OA1200300039A 2000-08-17 2001-08-08 Substituted imidazoles as tafia inhibitors. OA12362A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0020346A GB0020346D0 (en) 2000-08-17 2000-08-17 Pharmaceuticals
GB0027409A GB0027409D0 (en) 2000-11-09 2000-11-09 Pharmaceuticals
GB0029556A GB0029556D0 (en) 2000-12-04 2000-12-04 Pharmaceuticals

Publications (1)

Publication Number Publication Date
OA12362A true OA12362A (en) 2004-04-07

Family

ID=27255849

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200300039A OA12362A (en) 2000-08-17 2001-08-08 Substituted imidazoles as tafia inhibitors.

Country Status (38)

Country Link
EP (1) EP1311488B1 (ja)
JP (2) JP4119746B2 (ja)
KR (1) KR20030022412A (ja)
CN (1) CN1443173A (ja)
AP (1) AP1375A (ja)
AR (1) AR035580A1 (ja)
AT (1) ATE447557T1 (ja)
AU (1) AU2001276605A1 (ja)
BG (1) BG107330A (ja)
BR (1) BR0113289A (ja)
CA (1) CA2419633C (ja)
CY (1) CY1109693T1 (ja)
CZ (1) CZ2003388A3 (ja)
DE (1) DE60140368D1 (ja)
DK (1) DK1311488T3 (ja)
DO (1) DOP2001000233A (ja)
EA (1) EA005532B1 (ja)
EE (1) EE200300070A (ja)
ES (1) ES2334101T3 (ja)
HR (1) HRP20030103A2 (ja)
HU (1) HUP0303763A3 (ja)
IL (1) IL153225A0 (ja)
IS (1) IS6638A (ja)
MA (1) MA26940A1 (ja)
MX (1) MXPA03001425A (ja)
NO (1) NO20030706L (ja)
NZ (1) NZ522823A (ja)
OA (1) OA12362A (ja)
PA (1) PA8525401A1 (ja)
PE (1) PE20020352A1 (ja)
PL (1) PL361054A1 (ja)
PT (1) PT1311488E (ja)
SI (1) SI1311488T1 (ja)
SK (1) SK1732003A3 (ja)
SV (1) SV2002000602A (ja)
TN (1) TNSN01126A1 (ja)
UY (1) UY26889A1 (ja)
WO (1) WO2002014285A1 (ja)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103272D0 (sv) 2001-09-28 2001-09-28 Astrazeneca Ab Chemical compounds
BR0307033A (pt) 2002-01-22 2004-12-07 Pfizer ácidos 3-(imidazolil)-2-aminopropanóicos para o uso como inibidores tafi-a para o tratamento de doenças trombóticas
JP2005520811A (ja) * 2002-01-22 2005-07-14 ファイザー・インク ＴＡＦＩａインヒビターとしての３−（イミダゾリル）−２−アルコキシプロパン酸
US6713496B2 (en) 2002-01-22 2004-03-30 Pfizer Inc 3-(imidazolyl)-2-alkoxypropanoic acids
US8512675B2 (en) 2003-04-29 2013-08-20 Mallinckrodt Llc N and/or Nα derivatized, metal and organic protected L-histidine for coupling to biomolecules for highly efficient labeling with [M(OH2)3 (CO)3]+ by fac coordination
SE0302853D0 (sv) * 2003-10-29 2003-10-29 Astrazeneca Ab Chemical compounds
EP2338490A3 (en) * 2003-11-03 2012-06-06 Probiodrug AG Combinations useful for the treatment of neuronal disorders
WO2005051384A1 (en) * 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
WO2006113247A1 (en) * 2005-04-18 2006-10-26 Bayer Schering Pharma Aktiengesellschaft Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci
DE102005049385A1 (de) 2005-10-15 2007-04-19 Sanofi-Aventis Deutschland Gmbh Imidazolderivate als Inhibitoren von TAFIa
KR20090087044A (ko) * 2006-12-06 2009-08-14 사노피-아벤티스 ＴＡＦＩａ 억제제로서의 요소 및 설파미드 유도체
WO2009103432A2 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Covalently binding imaging probes
WO2010050525A1 (ja) * 2008-10-29 2010-05-06 大正製薬株式会社 ＴＡＦＩａ阻害活性を有する化合物
FR2947266B1 (fr) * 2009-06-26 2011-06-17 Servier Lab Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR20130006620A (ko) 2010-03-18 2013-01-17 다이이찌 산쿄 가부시키가이샤 시클로프로판카르복실산 유도체
RU2572814C2 (ru) 2010-03-18 2016-01-20 Дайити Санкио Компани, Лимитед ЦИКЛОАЛКИЛ-ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ ИМИДАЗОЛА, ОБЛАДАЮЩЕЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ TAFIa
SI2716684T1 (sl) * 2011-05-17 2019-11-29 Pharmasyntez Spojine za profilakso in postopek za zdravljenje adhezijskega postopka
WO2013014428A1 (en) * 2011-07-22 2013-01-31 Cambrex Karlskoga Ab New processes for preparing 4-substituted imidazoles
WO2013039202A1 (ja) * 2011-09-15 2013-03-21 第一三共株式会社 新規アクリル酸誘導体
RU2015156612A (ru) 2013-06-10 2017-07-17 Санофи Макроциклические производные мочевины в качестве ингибиторов tafia, их получение и их применение в качестве фармацевтических средств
MA52098A (fr) 2015-10-07 2021-01-27 Mitobridge Inc Agonistes de ppar, composés, compositions pharmaceutiques et leurs procédés d'utilisation
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2017170460A1 (ja) 2016-03-29 2017-10-05 第一三共株式会社 炎症性腸疾患治療剤
ES2861503T3 (es) * 2016-04-13 2021-10-06 Mitobridge Inc Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos
CN113943255B (zh) * 2020-07-17 2024-08-06 深圳信立泰药业股份有限公司 一种手性3-(4-环丙基-2,5-二氧杂咪唑啉-4-基)丙酸的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6163661A (ja) * 1984-09-05 1986-04-01 Microbial Chem Res Found ヒスタジン関連化合物
US5993815A (en) * 1996-11-08 1999-11-30 University Of Vermont Methods and compositions for inhibiting the activation of thrombin-activatable fibrinolysis inhibitor (TAFI)
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds

Also Published As

Publication number Publication date
CA2419633C (en) 2011-05-10
NO20030706D0 (no) 2003-02-14
PT1311488E (pt) 2009-12-30
BR0113289A (pt) 2003-06-17
JP2008169224A (ja) 2008-07-24
PL361054A1 (en) 2004-09-20
IS6638A (is) 2002-11-28
HRP20030103A2 (en) 2003-04-30
CZ2003388A3 (cs) 2004-03-17
JP2004506044A (ja) 2004-02-26
ES2334101T3 (es) 2010-03-05
SV2002000602A (es) 2002-10-24
SI1311488T1 (sl) 2010-01-29
CY1109693T1 (el) 2014-08-13
EA005532B1 (ru) 2005-04-28
NZ522823A (en) 2004-11-26
BG107330A (en) 2003-06-30
UY26889A1 (es) 2002-03-22
AU2001276605A1 (en) 2002-02-25
AP2001002250A0 (en) 2001-09-30
EA200201239A1 (ru) 2003-08-28
PA8525401A1 (es) 2002-04-25
MA26940A1 (fr) 2004-12-20
CN1443173A (zh) 2003-09-17
DE60140368D1 (de) 2009-12-17
EP1311488B1 (en) 2009-11-04
KR20030022412A (ko) 2003-03-15
DK1311488T3 (da) 2010-01-04
EE200300070A (et) 2005-02-15
HUP0303763A3 (en) 2004-06-28
WO2002014285A1 (en) 2002-02-21
IL153225A0 (en) 2003-07-06
SK1732003A3 (en) 2004-08-03
AP1375A (en) 2005-03-03
NO20030706L (no) 2003-04-15
PE20020352A1 (es) 2002-05-11
JP4119746B2 (ja) 2008-07-16
JP4778531B2 (ja) 2011-09-21
ATE447557T1 (de) 2009-11-15
MXPA03001425A (es) 2003-06-06
CA2419633A1 (en) 2002-02-21
DOP2001000233A (es) 2002-05-15
AR035580A1 (es) 2004-06-16
HUP0303763A2 (hu) 2004-04-28
TNSN01126A1 (fr) 2005-11-10
EP1311488A1 (en) 2003-05-21

Similar Documents

Publication Publication Date Title
OA12362A (en) Substituted imidazoles as tafia inhibitors.
US10308632B2 (en) Antifungal compounds and processes for making
CZ20003890A3 (cs) Substituovaný benzamid, způsob jeho přípravy a jeho pouľití jako inhibitoru cysteinproteasy
CZ287610B6 (cs) Pentanamidové deriváty a farmaceutický prostředek s jejich obsahem
TW201240975A (en) Metalloenzyme inhibitor compounds
US6919457B2 (en) 3-(imidazolyl)-2-aminopropanoic acids
EA002971B1 (ru) Ингибиторы металлопротеаз матрикса, способы их получения, фармкомпозиция, применение и способ лечения
HRP20040659A2 (en) 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
US6713496B2 (en) 3-(imidazolyl)-2-alkoxypropanoic acids
US6949577B2 (en) Pharmaceuticals
JP3588363B2 (ja) キノキサリンジオン類
JPH05504146A (ja) シクロアルキル置換グルタルアミド降圧剤
US20020147229A1 (en) Pharmaceuticals
TWI692476B (zh) 環丁基-咪唑啶酮化合物
JPH10510534A (ja) ２−（２，３，５，６−テトラフルオロ−４−ピリジル）−１，２，５−チアジアゾリジン−３−オン＝１，１−ジオキシド並びにその組成物及び使用方法
ZA200301230B (en) Substituted imidazoles as tafia inhibitors.
AU2003237012A1 (en) 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
JPS63270649A (ja) ５−置換アミノ−４−ヒドロキシペンテン酸誘導体及びその用途
JPH02196723A (ja) リン含有酵素阻害剤
JP2002541256A (ja) 新規エンドセリン転換酵素阻害剤、その製造および使用